Pluri Inc. · NASDAQ:PLUR
Pluri — Investor Presentation (March 2026)
22 slides from Pluri's investor presentation, March 2026
Slide 1: Where Technology Comes to Life
WHERE TECHNOLOGY COMES TO LIFE Q1 2026
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation contains forward-looking statements within the Israeli Securities Law, 1968, the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws, as amended, regarding Pluri Inc. and/or its subsidiaries (collectively the “Company” o
Slide 3: Pluri Venture Creation
Pluri Venture Creation Company Sectors Partners Regenerative ~$14 million Medicine and (as of December 31, 2025) wellness Cultivated Meat ~ Cell-Based Agriculture
Slide 4: Eight Billion Lives. One Planet. Zero Time to Waste.
Eight Billion Lives. One Planet. Zero Time to Waste. Aging and Health Climate Change Food Security Sustainability A growing, aging world urgently needs scalable, sustainable solutions
Slide 5: Pluri Technological Platform
Pluri Technological Platform Innovative Validated
Slide 6: Bio-Farming: Industrial Scale Production
Bio-Farming: Industrial Scale Production PluriMatrix
Slide 7: Single Platform, Various Verticals
Single Platform, Various Verticals Cultivated coffee 100% ownership Medical aesthetics & wellness 100% ownership Cultivated cacao 79% ownership Breakthrough cellular technology for the next generation of skin therapies Cell-based agriculture and regenerative medicine • Funded POC with ICL • Funded P
Slide 8: From Partnership to Independence: A Proven Path to Value Creation
From Partnership to Independence: A Proven Path to Value Creation Pluri holds a majority ownership stake in all its partner companies
Slide 9: Growing the Future of Food with Cultivated Meat
Growing the Future of Food with Cultivated Meat Ever After Foods leverages Pluri’s cell expansion technology to produce mass scale, cost-effective food products in an efficient and sustainable manner, aiming to solve the industry’s scalability challenges Environmental Ethical Consumer ● Less land an
Slide 10: Ever After Foods Milestones
Ever After Foods Milestones Expected completion of manufacturing system development, initiation of regulatory processes, and receipt of initial regulatory approvals in selected markets Granted exclusive global royalty-bearing license to use its IP and expertise I $7.5 million according to a $40 mill
Slide 11: Reimagining Coffee Without Ecological Cost
Reimagining Coffee Without Ecological Cost Climate Change Land Shortage decrease reduce Price Instability Carbon Footprint risen water
Slide 12: The Coffeesai Solution uses 100% Real Coffee
The Coffeesai Solution uses 100% Real Coffee Drying Roasting Brewing
Slide 13: A Consistent Methodology for Rapid, De-risked Venture Creation
A Consistent Methodology for Rapid, De-risked Venture Creation
Slide 14: Cacao at risk due to climate change
Cacao at risk due to climate change Unstable supply Rising prices $11,000 Complex supply chain Cocoa market growth Inconsistent quality $13.5
Slide 15: Kokomodo Milestones
Kokomodo Milestones kokomodo Cultivating Cocoa’s Future Feb. May H2 2026 2024 2025 2025 Company founded by Plantae Completion of acquisition by Pluri POC deals with Completion of development Bioscience, The Kitchen Y global partners processes to scale up (a Strauss Group company), plu ~79% ownership
Slide 16: Health and Wellbeing
Health and Wellbeing
Slide 17: Revolutionizing Beauty and Wellness Through Cell Science
Revolutionizing Beauty and Wellness Through Cell Science Market Science-Driven Opportunity Innovation $200B From Therapy to Partnership & Lifestyle Growth
Slide 18: Stem Cell Use Authorization in the US
Stem Cell Use Authorization in the US Premium Aesthetics Solutions The U.S. Food and Drug Administration (FDA) has authorized Mayo Clinic to offer mesenchymal stem cells as part of the Regenerative Nephrology Compassionate Use Program.
Slide 19: Key Milestones for 2026
Key Milestones for 2026 Achieving significant milestones with existing strategic Medical aesthetics & Plecental cells: partners, expanding collaborations with additional Accelerating product commercialization in the US partners, and regulatory filings in the US and Israel. and Europe, starting signi
Slide 20: Our Collaborative Network of Partnerships
Our Collaborative Network of Partnerships Regulatory Scientific Collaborations Funding and Partnering
Slide 21: Our Team
Our Team Yaky Yanay Liat Zalts Lior Raviv Dr. Michal Sheleg, PhD Nimrod Bar Zvi CEO & President Chief Financial Officer Chief Technology Officer VP Clinical Development Chief Commercial Officer Dr. Arthur Machlenkin, PhD Nofar Glaich-Dabach Orly Amiran Efrat Kaduri Ori Shalem Chief Scientific Office
Slide 22: Thank You
THANK YOU. Our cell-based innovations are aimed at transforming industries with a goal to create a more sustainable, healthier world. From the food we eat to the medicine we consume, we are building solutions that can potentially serve humanity, one breakthrough at a time. For further info: investor